L. A. Magee, A. Pels, M. Helewa, R. E. Von-dadelszen, and P. , Canadian hypertensive disorders of pregnancy working group; diagnosis, evaluation, and management of the hypertensive disorders of pregnancy, Pregnancy Hypertens, vol.4, issue.2, pp.105-150, 2014.

E. A. Steegers, P. Von-dadelszen, J. J. Duvekot, R. Pijnenborg, and . Pre-eclampsia, Lancet, vol.376, issue.9741, pp.631-675, 2010.

A. K. Rao, Y. W. Cheng, and A. B. Caughey, Perinatal complications among different Asian-American subgroups, Am J Obstet Gynecol, vol.194, issue.5, pp.39-41, 2006.

L. M. Silva, M. Coolman, E. A. Steegers, V. W. Jaddoe, H. A. Moll et al., Low socioeconomic status is a risk factor for preeclampsia: the generation R study, J Hypertens, vol.26, issue.6, pp.1200-1208, 2008.

J. Evans, J. Heron, H. Francomb, S. Oke, and J. Golding, Cohort study of depressed mood during pregnancy and after childbirth, BMJ, vol.323, issue.7307, pp.257-60, 2001.

T. Field, Prenatal anxiety effects: a review, Infant Behav Dev, vol.49, pp.120-128, 2017.

N. I. Gavin, B. N. Gaynes, K. N. Lohr, S. Meltzer-brody, G. Gartlehner et al., Perinatal depression: a systematic review of prevalence and incidence, Obstet Gynecol, vol.106, issue.5, pp.1071-83, 2005.

L. H. Pedersen, The risks associated with prenatal antidepressant exposure: time for a precision medicine approach, Expert Opin Drug Saf, vol.16, issue.8, pp.915-936, 2017.

L. E. Ross and L. M. Mclean, Anxiety disorders during pregnancy and the postpartum period: a systematic review, J Clin Psychiatry, vol.67, issue.8, pp.1285-98, 2006.

S. Kendig, J. P. Keats, M. C. Hoffman, L. B. Kay, E. S. Miller et al., Consensus bundle on maternal mental health: perinatal depression and anxiety, Obstet Gynecol, vol.129, issue.3, pp.422-452, 2017.

A. Berard, A. Gaedigk, O. Sheehy, C. Chambers, M. Roth et al., Association between CYP2D6 genotypes and the risk of antidepressant discontinuation, dosage modification and the occurrence of maternal depression during pregnancy, Front Pharmacol, vol.8, p.402, 2017.

A. Berard and O. Sheehy, The Quebec pregnancy cohort--prevalence of medication use during gestation and pregnancy outcomes, PLoS One, vol.9, issue.4, p.93870, 2014.

S. E. Andrade, M. A. Raebel, J. Brown, K. Lane, J. Livingston et al., Use of antidepressant medications during pregnancy: a multisite study, Am J Obstet Gynecol, vol.198, issue.2, pp.194-195, 2008.

W. O. Cooper, M. E. Willy, S. J. Pont, and W. A. Ray, Increasing use of antidepressants in pregnancy, Am J Obstet Gynecol, vol.196, issue.6, pp.544-545, 2007.

A. Berard, J. P. Zhao, and O. Sheehy, Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec pregnancy cohort, BMJ Open, vol.7, issue.1, p.13372, 2017.

E. Jimenez-solem, Exposure to antidepressants during pregnancy--prevalences and outcomes, Dan Med J, vol.61, issue.9, p.4916, 2014.

H. Zoega, H. Kieler, M. Norgaard, K. Furu, U. Valdimarsdottir et al., Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland, Norway and Sweden, PLoS One, vol.10, issue.12, p.144474, 2015.

M. P. Freeman, L. Goez-mogollon, K. A. Mcinerney, A. C. Davies, T. R. Church et al., Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders, Gen Hosp Psychiatry, vol.53, pp.73-82, 2018.

G. E. Hanley and B. Mintzes, Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance, BMC Pregnancy Childbirth, vol.14, p.242, 2014.

T. Kurki, V. Hiilesmaa, R. Raitasalo, H. Mattila, and O. Ylikorkala, Depression and anxiety in early pregnancy and risk for preeclampsia, Obstet Gynecol, vol.95, issue.4, pp.487-90, 2000.

C. Qiu, S. E. Sanchez, N. Lam, P. Garcia, and M. A. Williams, Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study, BMC Womens Health, vol.7, p.15, 2007.

C. Qiu, M. A. Williams, R. Calderon-margalit, S. M. Cripe, and T. K. Sorensen, Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy, Am J Hypertens, vol.22, issue.4, pp.397-402, 2009.

S. Zhang, Z. Ding, H. Liu, Z. Chen, J. Wu et al., Association between mental stress and gestational hypertension/preeclampsia: a meta-analysis, Obstet Gynecol Surv, vol.68, issue.12, pp.825-859, 2013.

H. B. Guan, Y. Wei, L. L. Wang, C. Qiao, and C. X. Liu, Prenatal selective serotonin reuptake inhibitor use and associated risk for gestational hypertension and preeclampsia: a meta-analysis of cohort studies, J Women's Health (Larchmt), vol.27, issue.6, pp.791-800, 2018.

D. J. Newport, A. L. Hostetter, S. H. Juul, S. M. Porterfield, B. T. Knight et al., Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy, J Clin Psychiatry, vol.77, issue.11, pp.1538-1583, 2016.

L. A. Avalos, H. Chen, and D. K. Li, Antidepressant medication use, depression, and the risk of preeclampsia, CNS Spectr, vol.20, issue.1, pp.39-47, 2015.

D. Ocampo, M. Araneta, M. Macera, C. A. Alcaraz, J. E. Moore et al., Risk of gestational hypertension and preeclampsia in women who discontinued or continued antidepressant medication use during pregnancy, Arch Womens Ment Health, vol.19, issue.6, pp.1051-61, 2016.

K. Palmsten, S. Setoguchi, A. V. Margulis, A. R. Patrick, and S. Hernandez-diaz, Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?, Am J Epidemiol, vol.175, issue.10, pp.988-97, 2012.

S. Toh, A. A. Mitchell, C. Louik, M. M. Werler, C. D. Chambers et al., Selective serotonin reuptake inhibitor use and risk of gestational hypertension, Am J Psychiatry, vol.166, issue.3, pp.320-328, 2009.

K. A. Yonkers, K. Gilstad-hayden, A. Forray, and H. S. Lipkind, Association of Panic Disorder, generalized anxiety disorder, and benzodiazepine treatment during pregnancy with risk of adverse birth outcomes, JAMA Psychiatry, vol.74, issue.11, pp.1145-52, 2017.

A. Lupattelli, M. Wood, K. Lapane, O. Spigset, and H. Nordeng, Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: a study from the Norwegian mother and child cohort study, Pharmacoepidemiol Drug Saf, vol.26, issue.10, pp.1266-76, 2017.

F. Uguz, Is there any association between use of antidepressants and preeclampsia or gestational hypertension?: a systematic review of current studies, J Clin Psychopharmacol, vol.37, issue.1, pp.72-79, 2017.

Y. Giguere, J. Masse, S. Theriault, E. Bujold, J. Lafond et al., Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers, BJOG, vol.122, issue.3, pp.402-412, 2015.

S. Theriault, J. C. Forest, J. Masse, and Y. Giguere, Validation of early risk-prediction models for gestational diabetes based on clinical characteristics, Diabetes Res Clin Pract, vol.103, issue.3, pp.419-444, 2014.

S. Theriault, Y. Giguere, J. Masse, J. Girouard, and J. C. Forest, Early prediction of gestational diabetes: a practical model combining clinical and biochemical markers, Clin Chem Lab Med, vol.54, issue.3, pp.509-527, 2016.

C. Vachon-marceau, S. Demers, S. Markey, N. Okun, M. Girard et al., First-trimester placental thickness and the risk of preeclampsia or SGA, Placenta, vol.57, pp.123-131, 2017.

K. M. Deligiannidis, N. Byatt, and M. P. Freeman, Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring, J Clin Psychopharmacol, vol.34, issue.2, pp.244-55, 2014.

K. Probst-schendzielorz, R. Viviani, and J. C. Stingl, Effect of cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors, Expert Opin Drug Metab Toxicol, vol.11, issue.8, pp.1219-1251, 2015.

G. Latendresse, C. Elmore, and A. Deneris, Selective serotonin reuptake inhibitors as first-line antidepressant therapy for perinatal depression, J Midwifery Womens Health, vol.62, issue.3, pp.317-345, 2017.

J. Andersen, A. S. Kristensen, B. Bang-andersen, and K. Stromgaard, Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters, Chem Commun (Camb), vol.25, pp.3677-92, 2009.

S. S. Zhou, Y. M. Zhou, D. Li, and N. N. Chen, Preeclampsia and future cardiovascular risk: a point of view from the clearance of plasma vasoactive amines, Hypertens Pregnancy, vol.35, issue.1, pp.1-14, 2016.

K. Bjoro and S. Stray-pedersen, In vitro perfusion studies on human umbilical arteries. I. Vasoactive effects of serotonin, PGF2 alpha and PGE2, Acta Obstet Gynecol Scand, vol.65, issue.4, pp.351-356, 1986.

C. Gonzalez, M. A. Cruz, V. Gallardo, J. Albornoz, and I. Bravo, Serotonin-induced vasoconstriction in human placental chorionic veins: interaction with prostaglandin F2 alpha, Gynecol Obstet Investig, vol.35, issue.2, pp.86-90, 1993.

C. Gonzalez, M. A. Cruz, W. H. Sepulveda, and M. I. Rudolph, Effects of serotonin on vascular tone of isolated human placental chorionic veins, Gynecol Obstet Investig, vol.29, issue.2, pp.88-91, 1990.

M. H. Yousif, B. Chandrasekhar, E. A. Kadavil, and M. A. Oriowo, Noradrenaline-induced vasoconstriction in the uterine vascular bed of pregnant rats chronically treated with L-NAME: role of prostanoids, J Cardiovasc Pharmacol, vol.42, issue.3, pp.428-463, 2003.

K. Palmsten, K. F. Huybrechts, K. B. Michels, P. L. Williams, H. Mogun et al., Antidepressant use and risk for preeclampsia, Epidemiology, vol.24, issue.5, pp.682-91, 2013.

S. J. Korzeniewski, R. Romero, T. Chaiworapongsa, P. Chaemsaithong, C. J. Kim et al., Maternal plasma angiogenic index-1 (placental growth factor/ soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study, Am J Obstet Gynecol, vol.214, issue.5, pp.629-630, 2016.

P. Gathiram and J. Moodley, Pre-eclampsia: its pathogenesis and pathophysiolgy, Cardiovasc J Afr, vol.27, issue.2, pp.71-79, 2016.

M. S. Finkel, F. Laghrissi-thode, B. G. Pollock, and J. Rong, Paroxetine is a novel nitric oxide synthase inhibitor, Psychopharmacol Bull, vol.32, issue.4, pp.653-661, 1996.

I. Yaron, I. Shirazi, R. Judovich, D. Levartovsky, D. Caspi et al., Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures, Arthritis Rheum, vol.42, issue.12, pp.2561-2569, 1999.

M. E. Thase, Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients, J Clin Psychiatry, vol.59, issue.10, pp.502-510, 1998.